To navigate this growth, , Vice President of Marketing, at Q’Apel recognized an immediate need to upgrade their internal operations. Having previously used enterprise-scale solutions at larger companies, Estrada knew that Q’Apel’s small marketing team needed a more nimble, compliant foundation to support major product launches.

Estrada brought this vision to life by partnering with , Founder of Svasti AI. With two decades of medtech experience at firms like Abbott and Intuitive Surgical, Bellamkonda is an expert in medical device advertising and promotion (A&P) management. Together, Estrada and Bellamkonda led the transformation of Q’Apel’s promotional review process, along with strong support from the Vice President of Regulatory and Quality, Jennifer Mateus, ultimately selecting �Թϱ��� PromoMats Basics to streamline
compliance, eliminate administrative friction, and accelerate their speed to market.

Navigating a Complex Regulatory Landscape

Like many companies in the early commercialization phase, Q’Apel initially relied on its existing electronic Quality Management System (eQMS) for promotional material review. Upon joining the company, Estrada found the legacy system to be rigid, inflexible, and highly cumbersome. Bellamkonda notes that this “force-fitting” of promotional content into a manufacturing system is a common industry challenge that leads to several pain points:

This rigid structure created several operational bottlenecks right as Q’Apel was initiating a new marketing campaign. Estrada recalls the significant friction of the old workflow: “If something was not perfect, it had to be essentially resubmitted. There was a lot of going back to square one and we knew we needed a different path.”

Beyond internal efficiency, Estrada and his team had to keep an eye on a tightening external regulatory environment. Medtech companies face heightened scrutiny from the FDA regarding commercial materials. In 2025 alone, the FDA issued over 50 warning letters specifically related to medical devices, marking a significant increase from previous years.¹

For organizations in a growth phase, ensuring they have robust, dedicated systems for promotional review is no longer a luxury—it is a critical safeguard against industry-wide risks.

Why �Թϱ��� PromoMats Basics?

Q’Apel needed a dedicated, robust process to replace the inefficiency of manual or repurposed systems. However, as a smaller organization, enterprise-scale software initially felt out of reach.

By selecting �Թϱ��� PromoMats Basics, the company found a turnkey platform delivering core capabilities across MLR, claims, and digital asset management (DAM). It provided the essential end-to-end compliance solution Q’Apel needed without the cost or overhead of a traditional custom setup.

Estrada found the lack of complex customization was actually an asset for a team of their size.

Ultimately, this choice came down to embracing “Simplicity over Customization.” Not being able to heavily modify the software allowed Q’Apel to deploy rapidly and integrate seamlessly straight into a validated, secure workflow.

Specific benefits realized by the marketing organization included:

The Implementation Journey

While traditional software rollouts typically require months of complex project planning and custom development, PromoMats Basics is structured for rapid operational readiness. This ready-to-use system allows companies to adopt pre-optimized, industry-standard workflows from day 1.

Bellamkonda highlights that this straightforward accessibility allows organizations to focus less on technical setup and more on smoothly embedding the platform into their own compliance frameworks:

1. Validation Testing
   Instead of building a framework from scratch, teams run a basic test protocol leveraging �Թϱ���’s existing pre-validation materials. This documents that the system functions correctly in their environment, ensuring that they remain fully audit-ready.
2. Quality System Integration
   The new system was officially incorporated into Q’Apel’s broader quality framework by updating standard operating procedures (SOPs) and creating role-based work instructions. This effectively establishes �Թϱ��� as the system of record, cleanly separating promotional materials from standard manufacturing quality workflows.
3. Accessible Onboarding
   Utilizing standard, role-based work instructions, the marketing team picked up the interface quickly, transitioning into routing day-to-day materials with minimal training.

Realizing Tangible ROI: Speed, Compliance, and Efficiency

By replacing mismatched, manual quality workflows with a purpose-built solution, growing medtech organizations can transform promotional review from a bottleneck into a measurable business advantage:

Looking beyond domestic operations, the �Թϱ��� PromoMats Basics system can seamlessly scale to support international markets and can help scale a global approval process. Despite its lean internal team, Q’Apel actively sells solutions across more than 50 international markets, incorporating its global approval needs into the system with zero friction.

A proactive and robust MLR setup is the key to stronger protection and greater efficiency.

Reflecting on the total impact of the transition, Estrada notes that PromoMats Basics has been a “night and day game changer for us as an organization. We are very, very pleased and very grateful.”

Discover how �Թϱ��� PromoMats Basics delivers the foundation emerging medtech organizations need to simplify content creation and maintain audit-ready compliance at every stage of growth.

The post How Q’Apel Medical Transformed the Promotional Review Process for Global Growth first appeared on �Թϱ��� Medtech.

The post Abbott: The Power of a Unified Platform for Improved Commercial Outcomes first appeared on �Թϱ��� Medtech.

“What is unique about �Թϱ��� is the end-to-end capabilities. It’s not that you need the whole system at once; you can pick and choose what is best for your company at a particular time and then build upon that infrastructure.”
Lynn Meyers, Sr. Director of Clinical Operations, Siemens Healthineers

Learn more about how Radiometer automated clinical processes to help achieve 400% increase in IVD trial activity.

The post Automated Workflows and Real-Time Visibility for Diagnostics with �Թϱ��� eTMF and CTMS first appeared on �Թϱ��� Medtech.

The post Developing a Cloud Software Business Case first appeared on �Թϱ��� Medtech.

The post 2026 Medtech CRM Benchmark Report first appeared on �Թϱ��� Medtech.

The post How Q’Apel Optimizes Promotional Review to Drive Growth and Speed to Market first appeared on �Թϱ��� Medtech.

Executive Summary

Most medtechs know their digital ecosystems are underperforming. However, our research reveals that what is often dismissed as administrative friction has evolved into a full-scale insight gap that is now a primary barrier to commercial growth. To understand the depth of this industry challenge, we recently surveyed 57 global medtech leaders to define the specific strategic shifts required to break this cycle. What makes this research unique is a rare shift in perspective: senior executives now agree with the field that administrative burden is a direct threat to growth, not just a minor operational annoyance.

The Consensus from the Top

Unlike typical studies that focus on user frustration, this report highlights rare, unanimous agreement among leadership:

• 100% of VP+ level respondents categorize manual workload as a high-impact drag on growth—proving this is no longer just a minor IT headache, but a major bottleneck to hitting revenue targets.
• While middle management has developed workarounds to cope with subpar tools, 50% of C-level executives now describe their CRM as “below functional”. They recognize that a “passive archive” cannot inform a proactive commercial strategy.
• Budget size is actually a negative predictor of AI success. Due to application sprawl and legacy complexity, large enterprises (>$5B) trail mid-market and enterprise medtechs in AI maturity (46% vs. 64% and 67% respectively).

From “Filing Cabinet” to Strategic Engine

To bridge the insight gap (ranked as the #1 challenge), leadership must pivot from passive administration to predictive execution. The goal is no longer just tracking activity, but sharpening field precision and anchoring institutional memory.

To quantify this, we asked respondents to rate the potential value of operational CRM capabilities. The percentages below represent the overwhelming share of survey participants who identified these areas as either a “high value” or “critical value” priority for their organization.

• Strategic Alignment (90%): Unifying sales, marketing, and medical teams to act as a single source of truth.
• Revenue Protection (84%): Safeguarding existing accounts and market share by giving leadership early visibility into competitive threats, pricing pressures, and at-risk business before it impacts the bottom line.

This report moves past simply documenting the industry’s data problem to show you how to transform your sales solutions into a well orchestrated commercial asset. More importantly, it looks ahead at how next-generation technology can transform real-world field intelligence into strategic Commercial Evidence™ eliminating blind spots and protecting your revenue.

The Vicious Cycle of Medtech CRM

Over the past decade, medical device and diagnostics organizations have invested hundreds of millions of dollars into software designed to drive commercial success. Yet, despite this massive capital outlay, commercial teams are increasingly caught in a vicious cycle where administrative burden far outweighs strategic impact. While this tension isn’t new, it remains an unresolved problem.

This cycle functions as a self-reinforcing loop of diminishing returns:

Ultimately, this strategic paralysis results in missed quotas and slow growth at critical stages of the product lifecycle.

Leadership no longer views this as a minor IT inconvenience; they see it as a major bottleneck that prevents the company from responding to market shifts in real-time. Breaking this cycle requires more than a software patch; it requires an intentional shift away from passive record-keeping toward an AI-enabled future that delivers clear visibility into customer needs and proactively guides field interactions.

The Administrative Burden: A Barrier to Entry

While organizational silos rank slightly higher on our survey, the most immediate operational hurdle facing field teams today is the sheer volume of manual data entry. Research shows that 60% of respondents categorize administrative workload as a high-impact pain point for their organization.

This internal frustration matches broader industry data: 71% of field reps cite manual logging as the absolute biggest challenge to CRM utilization because it consumes too much time.¹

This heavy administrative workload drives a steep drop in user adoption, transforming the CRM from a valuable sales tool into a passive archive. Ultimately, when low adoption leaves commercial, medical, and market access teams operating out of sync, it creates critical tracking blind spots and directly leads to unrealized value.

The One-Way Filing Cabinet: Data Without Value

In practice, this passive archive operates as a one-way filing cabinet. Representatives enter only the bare minimum data required for management documentation, leaving the system devoid of the detail needed to sell effectively. This gap is clear in the research findings: while 39% of teams have successfully optimized activity logging, a mere 16% have achieved that same advanced level for customer intelligence to drive sales.

This lack of depth is compounded by a lack of participation; when data provides no value back to the field, adoption inevitably plateaus. Navigating with low adoption is like using half a map. Survey data shows that while 40% of organizations report majority CRM usage, only 19% have achieved universal adoption (defined as 75% or more of their field team).

When leadership tries to drive strategic business decisions using incomplete data they are operating with massive blind spots – leading to unreliable pipeline metrics and unpredictable forecasting.

This forecasting blind spot ripples across the entire organization. It creates deep cross-functional silos where sales, marketing, and medical teams – lacking a single, unified system – are forced to build workarounds.

As a result, each department begins operating on a completely different set of data actively blocking the broader organizational strategy.

This breakdown is where commercial execution falters:

• 65% say these silos are the primary reason their commercial strategy stalls.
• When commercial, medical, and market access teams operate out of sync, it leads to fractured targeting and weak clinical documentation – making the company highly vulnerable to payer friction. According to Counterforce Health², navigating these hurdles inefficiently results in permanent annual revenue leaks of up to $3,000,000 per device portfolio due to unrecovered insurance denials.
• Siloed data is “invisible” data. For instance, if the medical team uncovers a crucial clinical insight about a surgeon that never reaches the sales team, the rep walks blind and the company loses its competitive edge.

These numbers prove that the stakes have moved beyond simple field productivity. True commercial value comes from a system that seamlessly connects marketing content and automation tools directly to the CRM, providing full visibility into what actually works in the field. Leaders don’t need another way to track calls; they need to know exactly where reps are spending their time and how their top performers are driving commercial success. Ultimately, they need a platform that connects these disconnected functions and keeps their strategy on track.

Turning Information into Action: Bridging the Insight Gap

The ultimate consequence of low data quality and isolated functional silos is a guidance vacuum. Medtech teams no longer suffer from a lack of information but from an inability to turn that information into a clear plan. This insight gap is ranked by 68% of respondents as their #1 strategic challenge for 2026.

This gap is most visible in the disconnect between communication and targeting. Even when organizations possess the tools to reach a customer, they are often flying blind when deciding which customers to prioritize.

• 61% of medtechs report that their omnichannel delivery is only somewhat effective (the “how”).
• 35% rate their predictive intelligence – knowing exactly who to call on and when – as completely ineffective.

Strikingly, having a more advanced CRM does not automatically close this gap. Organizations that indicate they have an advanced “strategic engine” platform are actually more likely to flag the insight gap as a top challenge (73%) compared to those operating with basic systems. This occurs because an advanced system immediately exposes the “noise” of unorganized data the second a team attempts to leverage it for predictive guidance or AI models. This highlights a deeper infrastructure barrier: the platform cannot act as a navigator if its foundation is still just a passive archive.

Strategic Paralysis: The Infrastructure Barrier

Looking at the industry as a whole, a clear 61% majority of medtech organizations are stuck using their CRM as a basic database rather than a competitive edge. (see Figure 6).

This pain is felt acutely at the top, revealing a disconnect when you break the data down by leadership tier:
50% of C-level respondents describe their CRM capabilities as “below functional” (meaning the see them as a legacy constraint, an operational burden, or a manual process), compared to just 18% of frontline managers. Executives closest to the P&L recognize that the traditional filing cabinet model – which merely logs past activities – cannot help as sales team anticipate customer needs or target the right clinical opportunities.

Faced with systems that merely log past data rather than drive future strategy, medtech leaders are changing their priorities. They are shifting focus toward strategic alignment, knowledge retention, and revenue protection to stabilize their operational foundation:

• 90% cite strategic alignment as a top priority: This is the top demand for a reason. Internal silos are no longer viewed as just an operational annoyance – they are recognized as a primary barrier that keeps sales, marketing, and medical teams from working as a cohesive unit.
• 79% say knowledge retention, such as territory relationship continuity, is now a critical focus. With the total cost of losing a single medical device representative ranging from $150,000 to over $300,000 per open vacancy,³ leaders are prioritizing platforms that secure full account histories and clinic dynamics within the company so that vital relationships remain protected the moment a representative exits the territory.
• 84% identify revenue protection — specifically identifying at-risk accounts to prevent business loss — as a high-value necessity. By keeping teams aligned and ensuring territory data stays within the company, leadership can spot these vulnerabilities early and defend their market share before competitive threats hit the bottom line.

This shift proves that the goal has changed: it is no longer about just tracking activity, but about securing the institutional memory required to protect and grow the business.

AI: Breaking the Cycle

AI has the potential to break the vicious cycle of administrative burden, yet it remains the most hyped and least deployed tool at scale in medtech. While 89% of organizations have yet to deploy AI in a meaningful way, 51% see predictive analytics as the key to solving the “who and when” problem for their reps.

Budget size alone does not guarantee AI execution; instead, medium and enterprise organizations ($100M-$5B) are the clear leaders in the AI race.

As shown in Figure 10, active AI pilots and deployments peak among enterprise medtechs at 67%, closely followed by medium organizations at 64%. In contrast, the largest multi-billion-dollar conglomerates ($>5B) lag behind at just 46%. While smaller, emerging companies are often restricted by limited budgets (33%), global enterprises are bottlenecked by legacy IT system sprawl and rigid compliance protocols that stall rapid deployment.

Ultimately, you cannot automate what you haven’t organized. The primary barrier to scaling these solutions is data readiness. In fact, data infrastructure has become such a bottleneck that companies are projected to abandon 60% of AI deployments due to lack of clean, AI-ready data.⁴ The medtechs who stabilize their data foundation today will be the ones whose AI-enabled reps can accurately predict account needs, secure territory continuity, and protect market share tomorrow.

The Medtech Commercial Maturity Roadmap

Moving your organization forward requires transforming your CRM from a digital filing cabinet into an active tool that helps your field teams sell. This transformation demands more than modernizing your software; it requires a fundamental shift in how you capture, understand, and use real-world market insights. Below is the path to moving your commercial organization past the tracking stage and into a strategic, data-driven engine:

From Manual to Connected

Break the adoption plateau by automating data entry – using AI tools to easily document call reports in the field – so your team gets their selling time back while effortlessly capturing the rich, qualitative details of their clinical interactions.

From Connected to Empowered

Move away from fragmented databases to an industry-specific platform that keeps account histories and clinical insights in one place. Clean up your data house now, as establishing high-integrity data today is the one way to eliminate blind spots and enable advanced enterprise workflows tomorrow.

From Empowered to AI-Enabled

Enable reps with internal and external market signals to help them prioritize their day without hunting for information. Bridge the insight gap by embedding smart prompts directly into the rep’s daily workflows so they know exactly which accounts to prioritize and when.

AI-Enabled Field Workflows

Move to a system that is AI-enabled to give the field a true competitive advantage with the right targets at the most impactful moments.

The Next Frontier: Agentic Commercial™ and Commercial Evidence™

Reaching the AI-Enabled stage of the maturity roadmap is not a final destination; it is the launchpad into Agentic Commercial™ execution – a proactive, coordinated ecosystem where digital agents, field teams, and content work together to uncover real-world treatment barriers.

At its core, this model turns unstructured field interactions into Commercial Evidence™ – capturing the critical nuances that standard CRMs lose, and translating them into actionable sales insights. By capturing this deep qualitative context at scale, an agentic framework gives leadership the precise evidence needed to expose hidden roadblocks and maximize commercial agility.

�Թϱ��� Commercial Cloud provides the unified technology foundation for this agentic future, connecting sales, marketing, and medical teams on a single platform to achieve true customer centricity. Through tools like the Agentic Call Report™ in Vault CRM, field teams can compliantly capture detailed notes using natural voice and free text—moving from restrictive dropdowns to complete context. This real-world intelligence empowers organizations to sharpen target segmentation, deliver precise field suggestions that accelerate patient treatment, and dynamically tailor marketing campaigns to the immediate needs of healthcare providers.

Learn how a purpose-built CRM solution can help close the insight gap and become a strategic engine.

Demographic Summary of Survey:

• Figures rounded for clarity.
• Online survey of 57 commercial operations, sales, marketing, and IT leaders in the medtech industry, January – March 2026.

<sup>1. Source: Clari Revenue Intelligence Research, 2024.


2. Source: Counterforce Health, 2025.


3. Source: 3MDliaison, 2026.


4. Source: Deloitte Tech Trends, 2026.</sup>

The post 2026 Medtech CRM Benchmark Report first appeared on �Թϱ��� Medtech.

Abstract

Medical device and IVD regulatory systems rely on legacy, document-centric regulatory submissions. In practice, this means large volumes of information are recreated, reformatted, checked manually, and resubmitted in different ways across jurisdictions and review bodies. This results in too much time spent managing submission lifecycles, rather than assessing critical priorities: product safety, performance, and timely patient access.

With this in mind, and co-hosted a regulatory executive roundtable, convening more than 20 senior leaders from medical device and IVD manufacturers, consultants, approved/notified bodies, and trade associations to define the essential elements of a modernized, proactive digital regulatory framework designed to streamline global conformity assessments.

This paper details a practical case for a unified digital model that is built on structured, reusable data instead of static document packages and is both open standards-based and solution-agnostic.

Introduction

Across the medical device and IVD sector, a persistent challenge has been the continued reliance on document-based submissions that are resource-intensive, difficult to maintain, and poorly suited to the scale and complexity of modern regulation. Reflecting the collective experience behind this paper, spanning more than 300 years in global submissions, the issue is not the absence of data, but the fact that critical regulatory information is too often locked within static, narrative-driven documents. This creates duplication for manufacturers, avoidable inefficiency for regulators and notified bodies, and a process that can divert attention from the central purpose of regulation: ensuring safety, performance, and timely patient access to innovation.A more modern approach is now needed, based on structured, interoperable data that can support clearer submissions, more consistent review, and greater efficiency across the product lifecycle.

To maintain global competitiveness and accelerate patient access to innovative products, medtech manufacturers need to move beyond static PDFs that lock data in an unusable state to a simplified, system-agnostic digital framework. This evolution is fundamental for a transparent, compliance-by-design model.

Replacing manual, document-centric workflows with an integrated, data-first system shifts the focus from navigating administrative hurdles to proactively ensuring the safety and performance of life-saving devices and diagnostics. Embracing these opportunities allows the medtech industry to resolve structural inefficiencies and accelerate patient access through a standardized electronic submission framework.

Traditional submission formats lack the structure needed for automated review and data or document exchange, leading to:

• Manual Data Entry: Teams spend significant time and resources duplicating, reformatting, and rectifying data within and across submissions. that over 30% of professional staff time in conformity assessments is dedicated to administrative tasks instead of core clinical, technical, and compliance reviews.
• Process Complexity: Regulatory frameworks such as the EU MDR and IVDR require extensive and at times duplicative documentation. This is often the result of duplication, where the same information is utilized in different contexts within the regulation. Furthermore, one of the main reasons for rejection of applications for conformity assessment is submission incompleteness.

Value of a Data-First Digital Framework

A standardized, system-agnostic digital framework would deliver clear benefits across the healthcare ecosystem, such as:

• Accelerated Market Access: A digital framework would shorten approval timelines and reduce turnaround time for post-market changes, allowing innovative products to reach patients faster. A standardized format can facilitate reviews and allow for immediate and complete identification of areas of change when submissions are updated.
• Enhanced Regulatory Capacity: Reducing manual burden and bureaucratic noise can free up capacity within both manufacturers and regulatory bodies, allowing teams to focus on identifying and addressing actual safety issues rather than administrative documentation inconsistencies. Further, the standardization of data format can enable additional efficiency gains through the use of AI. This is especially important for SMEs who have limited regulatory capacity but form 90% of the industry.
• Operational Efficiency: A standardized framework can provide a clear return on investment by lowering the cost of compliance, both for SMEs and large manufacturers alike, helping prevent good ideas from running out of funding or reaching patients while waiting for certification decision or approval.
• Global Reliance and Scalability: A unified data foundation can enable frictionless data exchange across health authorities. If core regulatory elements are globally harmonized, a single structured dataset can support multiple geographies, requiring only minimal, region-specific data variants to scale globally.
• Data Portability: A standardized framework for data portability can support M&A activities and portfolio transfers. Technical documentation would no longer require manual refactoring to align with an acquiring company’s quality management system (QMS). Similarly, standardization can streamline transition between conformity assessment bodies.
• Increased Transparency: Well structured and traceable technical documentations can facilitate assessments/audits and enable easier maintenance through the product’s lifecycle.

Ten Elements to Streamline

This position paper outlines the ten essential elements required to build a streamlined regulatory future, centered on simplification and transparency. By moving from a reactive cycle of administrative correction to a proactive model of data-driven compliance, we can ensure a system framework that serves all stakeholders equally.

1. Standardized, Data-First Framework

The system must transition from narrative-heavy, unstructured documents to a standardized product-level dataset. This simplifies the submission process by reducing subjective interpretation, eliminating variation and error where elements are reused, and allowing for scalable and consistent interrogation by regulators or approved/notified bodies.

2. Uniformity Across Stakeholders and Lifecycle Stages

A single source of truth provides consistent information to manufacturers, regulators, and approved/notified bodies. This uniform submission layer allows all parties to leverage conformity assessment outcomes from other jurisdictions without full reassessment of underlying evidence, reducing parallel or sequential assessments of substantively similar technical documentation. Clear data definitions also ensure consistent information use across different lifecycle stages within the same organization or jurisdiction.

3. Standardized Coding for Deficiencies, Findings, and Remediations

Utilizing a harmonized global coding system provides unprecedented transparency into submission queries and rejections. Similarly, there should be reciprocal coding from the manufacturer denoting what has been done to address the issues raised. This dual-coding mechanism allows stakeholders to address systemic bottlenecks proactively before filing. Standardizing these data insights drives continuous improvement of global conformity assessments.

4. Prospective-First Design

The digital framework should prioritize a prospective-first approach for new product submissions to accelerate market entry for innovation. Migrating existing legacy technical documentation into the new framework requires a phased approach, meaning the ecosystem must support both legacy formats and structured data during a significant transition period. This approach avoids disproportionate resource implications of retrospective digitalization for legacy medical devices and IVDs, particularly for Well Established Technologies (WET).

5. Universal Inclusivity

The framework must be free to access and available for startups, SMEs, and large companies alike. This open accessibility supports inclusive regulatory participation and avoids imposing disproportionate short-term compliance costs on smaller market entrants.

6. Data Integrity and Lifecycle Governance

To ensure the reliability of regulatory outputs, the system enforces strict data integrity standards that shift the operational focus from reactive correction to proactive lifecycle management. This architecture prevents the submission of inconsistent or non-compliant datasets, ensuring that critical information, such as post-market surveillance data, is accurately captured and trended throughout the device lifecycle. Automated validation confirms that submission sections are complete, structurally sound, and audit-ready at every stage, as well as ensuring that a submission that meets the validation standards is automatically a complete submission.

7. System-Agnostic Portability and Interoperability

The framework must be built on open-source principles and global data interoperability to ensure vendor-agnostic portability, with due regard to confidentiality, controlled access, and cyber security. This capability is critical for portfolio transfers during corporate housekeeping, M&A activities, co-development arrangements, and moving between different jurisdictions. Such transfers should be able to be implemented without substantive reformatting of documentation, as well as enabling manufacturers to transfer their regulatory data across systems or organizations, as required.

8. Global Harmonization

The roadmap to success should be global, leveraging frameworks like the IMDRF Reliance Playbook. Implementation should follow a phased, scalable pilot approach to progressively expand standards over time. To achieve true global alignment, this digital infrastructure must remain independent of specific regulators or conformity assessment bodies.

9. Artificial Intelligence Enablement

Structured data provides the robust foundation required to successfully apply AI. This enables medtech manufacturers and regulatory body professionals to focus on value-added activities required for increasingly complex evaluations, such as assessing safety and effectiveness of medical devices and IVDs.

10. Measurable Return on Investment

The framework must drive efficiency through the simplification of the review process, reducing administrative duplication of assessment activity and shortening review timelines both in a single jurisdiction and across markets. This frees up capacity within manufacturers and regulators or approved/notified bodies alike, supporting high value innovation over administrative remediation.

Conclusion

As healthcare rapidly transforms, the medtech industry’s reliance on outdated, document-centric workflows creates a widening gap between regulatory practices and technological progress. By adopting these ten elements, medtech manufacturers, regulatory authorities, and approved/notified bodies can move beyond the burden of reactive administrative correction, support manufacturers of all sizes, and embrace a model of proactive compliance by design. The transition to a digital regulatory system is therefore a necessity for medtech. This evolution centers on simplification and a transparent, data-rich environment where expectations are clear and outcomes are predictable. By ensuring this framework remains entirely system-agnostic, this digital regulatory approach protects the portability of innovation and prevents the fragmentation of global markets. A harmonized digital foundation will not only accelerate patient access to life-saving technologies but also provide the necessary infrastructure for safe and effective AI integration.

Moving beyond pilot programs requires a commitment across the industry to implement a unified global roadmap creating operational efficiency for all. By uniting around this shared vision, the medtech ecosystem can transform regulatory compliance from a bureaucratic hurdle into a strategic accelerator-one that upholds the highest standards of product safety and performance while ensuring timely patient access to life-saving innovations.

CO-AUTHORS

The post Ten Elements for a Streamlined Digital Regulatory Future first appeared on �Թϱ��� Medtech.

The post Philips & Roche Diagnostics: Leading Digital Change in Medical Affairs first appeared on �Թϱ��� Medtech.